ArticleBMC cancer2022
Is lobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Could less be enough: sublobar resection vs lobectomy for clinical stage IA non-small cell lung cancer patients with visceral pleural invasion or spread through air spaces.International journal of surgery (London, England) · 2025Pooled it
- Multi-component radiological model based on intratumoral CT threshold segmentation for predicting visceral pleural invasion in lung adenocarcinoma ≤ 30 mm.Insights into imaging · 2026Article
- Predicting visceral pleural invasion in invasive adenocarcinoma with a maximum diameter ≤ 3 cm based onEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Clinical TNM Lung Cancer Staging: A Diagnostic Algorithm with a Pictorial Review.Diagnostics (Basel, Switzerland) · 2025Review
- A nomogram for cancer-specific survival of lung adenocarcinoma patients: A SEER based analysis.Surgery open science · 2024Article
- Comparison of proximal and distal gastric neuroendocrine carcinoma based on SEER database.Scientific reports · 2024Article
- Pleural Invasion in Non-small Cell Lung Cancer: An Important Characteristic during Clinical Decision-Making.Annals of surgical oncology · 2024Article
- Using the length of pleural tag to predetermine pleural invasion by lung adenocarcinomas.Frontiers in oncology · 2024Article
- Association between radiotherapy for surgically treated oral cavity cancer and secondary lung cancer.Frontiers in public health · 2023Article
- Diagnosis, treatment, and prognosis of stage IB non-small cell lung cancer with visceral pleural invasion.Frontiers in oncology · 2023Review
- Prognostic factors of survival in patients with non-small cell lung cancer: a competing risk model using the SEER database.Translational cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPleural invasion (PL) has been regarded as an unfavorable prognostic factor for non-small cell lung cancer (NSCLC). But there was no agreement on the optimal surgical extent in NSCLC patients with PL. We aimed to compare the survival outcomes of lobectomy and sub-lobectomy in these patients.
method2717 patients were included in the Surveillance, Epidemiology, and End Results (SEER) database and divided into the lobectomy and sub-lobectomy groups. The propensity score matching (PSM) and competing risk analysis were implemented. Then the predictive nomogram was constructed and validated.
results2230 Patients received lobectomy while the other 487 patients underwent sub-lobectomy. After 1:1 PSM, the cumulative incidence of cancer-specific death (CSD) was lower in the lobectomy group compared with the sub-lobectomy group (1-year: 12% vs. 15%; 3-year: 30% vs. 37%, 5-year: 34% vs. 45%, P = 0.04). According to the subgroup analysis, the patients who underwent lobectomy suffered lower CSD in the N0-1 stage, adenocarcinoma, and PL-2 cohort (p < 0.05). And there was a significant relationship between the sub-lobectomy group and CSD in the multivariate competing risks regression analysis (HR, 1.26; 95%CI, 1.02-1.56; P = 0.034). Furthermore, a competing event nomogram was constructed to assess the 1-, 3-, and 5-year chances of CSD based on the variables from the multivariate analysis. The 1-, 3-, 5-year area under the receiver operating characteristic curve (AUC) values were 0.720, 0.706, and 0.708 in the training cohort, and 0.738, 0.696, 0.680 in the validation cohorts, respectively. And calibration curves demonstrated ideal consistency between the predicted and observed probabilities of CSD.
conclusionLobectomy should be considered the preferred surgery compared to sub-lobectomy for NSCLC patients with PL. The proposed nomograms presented great prediction ability for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.